Drug Database
IN

insulin (Univia / rh Insulin / Insulin R)

✓ Approved

Bayer AG · INSR · 重组蛋白

什么是 insulin?

insulin 是一种重组蛋白,由Bayer AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名Univia, rh Insulin, Insulin R
公司Bayer AG
药物类别重组蛋白, 多肽类
分子靶点INSR
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

insulin 作用于 1 个分子靶点:

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

insulin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedJournal of biomedical science2026-11-17

Genetic and pharmacological inactivation of soluble epoxide hydrolase ameliorates diet-induced MASH.

Mello Aline A, Hsu Ming-Fo MF, Yang Jun J, Torok Natalie N et al.

Metabolic dysfunction-associated steatohepatitis (MASH) is the most common chronic liver disease worldwide. Pharmacological interventions for MASH remain limited, establishing the need to identify and validate novel therapeutic targets. Soluble epoxide hydrolase (sEH; EPHX2) hydrolyzes anti-inflammatory epoxy fatty acids into less bioactive diols. We investigated the role of hepatic sEH in MASH using genetic and pharmacological approaches. Expression of hepatic EPHX2 was determined in liver samples from MASH patients and control subjects. We also fed control (Ephx2fl/fl) and liver-specific sEH-deficient mice (Alb-Cre; Ephx2fl/fl) either regular chow or a fructose-supplemented fast-food diet (FFD) for 27 weeks. We evaluated metabolic parameters and markers of liver injury, steatosis, inflammation, and fibrosis, as well as oxylipin profiling. Moreover, we treated FFD-fed control mice with the sEH pharmacological inhibitor TPPU in preventive, early, and late therapeutic intervention modalities. We report significant elevation in hepatic EPHX2 in MASH patients compared with controls. Hepatic sEH deficiency improved glucose tolerance, with trends toward lower fasting glucose and fed insulin levels, independent of body weight. Remarkably, hepatic sEH deficiency ameliorated FFD-induced liver injury, steatosis, and lipid dysregulation. Additionally, sEH deficiency mitigated hepatic and systemic inflammation and fibrosis triggered by prolonged FFD feeding. Furthermore, sEH deficiency remodeled the hepatic oxylipin profile and preserved anti-inflammatory epoxides. Importantly, sEH pharmacological inhibition recapitulated these findings, significantly reducing liver injury and steatosis, inflammation, and fibrosis in the FFD across preventive and therapeutic intervention modalities, with the greatest effect in the preventive arm. Together, these findings establish that genetic and pharmacological inactivation of sEH rebalances the oxylipin landscape, enhances the metabolic profile, and ameliorates steatosis, inflammation, and fibrosis in a dietary mouse model of MASH. The concordance between the genetic and pharmacological approaches, along with the efficacy of sEH inhibition across preventive and therapeutic modalities, supports developing sEH-targeted interventions for MASH.

PMID 43040330
阅读全文 →
PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedNature metabolism2026-11-17

Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk.

Kjærgaard Jeppe J, Kurgan Nigel N, Gräf Justus F JF, Zhang Naixin N et al.

Insulin resistance drives cardiometabolic disease, yet its molecular signatures and tissue origins remain incompletely characterized. Here we define a circulating protein signature that enables scalable assessment of insulin sensitivity. We applied multiworkflow proteomics to plasma from 161 individuals spanning the insulin sensitivity spectrum defined by the hyperinsulinaemic-euglycaemic clamp and identified 488 proteins associated with insulin sensitivity, capturing contributions from liver, adipose tissue and immune cells. A subset of these proteins shifted towards a more insulin-sensitive profile following an exercise intervention in men. We further developed a model combining 13 proteins, including IGFBP1, LEP, GDF15, PON3 and LDLR, with clinical variables (sex, HbA1c and the triglyceride-to-high-density lipoprotein cholesterol ratio) to predict insulin sensitivity (R2 = 0.67). In ~20,000 UK Biobank participants, the model outperformed the triglyceride-to-high-density lipoprotein cholesterol ratio in predicting type 2 diabetes (concordance index, 0.86 versus 0.74) and, unlike HbA1c, predicted hepatic, renal, cardiovascular and respiratory disease. In an independent cohort of 1,700 individuals, the model also showed greater predictive utility than fasting insulin resistance indices, including the homeostatic model assessment of insulin resistance. Together, these findings establish a tissue-resolved plasma proteomic framework for characterizing insulin resistance and provide a scalable approach to precision cardiometabolic risk stratification.

PMID 43040099
阅读全文 →
PubMedBMC biology2026-11-17

Drosophila CerS homeodomain sites differentially alter insulin resistance.

Vera-Granda Christian C, Sociale Mariangela M, Beckschäfer Konstantin K, Kanevskij Ilja I et al.

Ceramides are central sphingolipid intermediates whose abundance and molecular composition are closely linked to insulin resistance. Ceramide synthases (CerSs) generate ceramides and, in several family members, also contain a conserved homeodomain with poorly understood metabolic functions. Drosophila has a single CerS, Schlank, which contains a catalytic Lag1p motif and two predicted nuclear localization sequences, NLS1 and NLS2. We investigated how distinct Schlank homeodomain mutations affect high-sugar diet (HSD)-induced insulin resistance. Endogenous KINLS1 and KIE118A knock-in alleles retained DNA binding and transcriptional repression under basal conditions but increased susceptibility to HSD-induced metabolic dysfunction. Both mutants developed enhanced hyperglycemia and impaired insulin-responsive tGPH recruitment, while KIE118A additionally showed increased FoxO nuclear localization and DILP2 retention in insulin-producing cells. By contrast, fat-body-specific switching to the DNA-binding-deficient NLS2 variant or the catalytically inactive H215D variant attenuated selected HSD-induced phenotypes, including FoxO nuclear accumulation and DILP2 retention, without fully correcting hyperglycemia or reduced body weight. Lipidomic analysis revealed extensive diet-dependent sphingolipid remodeling. In particular, NLS2 and H215D markedly reduced the fat-body ceramide pool, including abundant d14:1/20:0- and d14:1/22:0-containing Cer, CerPE, and HexCer species. The Schlank homeodomain regulates insulin homeostasis in a site- and tissue-dependent manner. Distinct homeodomain mutations can either increase susceptibility to or partially attenuate HSD-induced insulin resistance, potentially involving insulin signaling, inter-organ communication, and sphingolipid composition.

PMID 43040328
阅读全文 →
PubMedEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)2026-11-17

Healthy lifestyle adherence and insulin resistance in prostate cancer patients undergoing radiotherapy: baseline findings from the MicroStyle study.

Doi Giulia G, Bellerba Federica F, Repetti Ilaria I, Mazzocco Ketti K et al.

Radiotherapy in prostate cancer (PCa) may induce side effects and reduced quality of life (QoL). Diet and physical activity may improve prognosis and treatment outcomes, potentially through modulation of insulin resistance. The aim of this cross-sectional subanalysis of the MicroStyle trial is to investigate the association of adherence to a healthy lifestyle with insulin resistance in PCa patients before radiotherapy, and to study the interrelations between lifestyle adherence, insulin resistance, hormonal biomarkers, inflammatory, and psychosocial variables. Insulin resistance was measured via Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Lifestyle adherence was quantified using the World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) score, and participants were classified as adherent if they had a WCRF/AICR score above the cohort median. Associations between WCRF/AICR adherence, HOMA-IR, biomarkers, and psychosocial factors were evaluated using univariate and multivariable logistic regression, supported by network analysis. Baseline adherence to WCRF/AICR recommendations was independently associated with lower HOMA-IR, with approximately 60% significantly lower odds of insulin resistance (odds ratio = 0.39, 95% confidence interval: 0.22-0.67). Higher HOMA-IR was observed in patients on hormone therapy (P < 0.001) and those with a stronger tendency to control others (P = 0.02), adjusting for sex hormone-binding globulin (P < 0.001) and adiponectin (P = 0.01), which emerged as significant biomarkers. This study revealed clear associations between lifestyle, metabolic health, and psychological factors. Promoting a healthy lifestyle and psychological support in PCa patients may improve metabolic health.

PMID 43040935
阅读全文 →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-11-17

Investigating the association between blood lipid profiles and insulin resistance and β-cell function indices in pregnant women.

Feng Jie J, Xu Xinyue X, Tian Zeyang Z, Chen Fangbo F et al.

This study aimed to examine the associations between first-trimester lipid markers and second-trimester insulin resistance (IR) and pancreatic β-cell function (BCF) indices in pregnant women. An exploratory aim was to explore the apparent discrimination of lipid markers for cohort-defined low insulin sensitivity. This retrospective secondary analysis used prospectively collected cohort data from 1202 pregnant women in Beijing, China. Lipids were measured at 4-8 weeks of gestation, and a 75 g oral glucose tolerance test was performed at 24-28 weeks. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and the Matsuda index were analyzed as continuous measures of IR and insulin sensitivity. BCF was assessed using surrogate indices: the Homeostatic Model Assessment of β-cell function (HOMA-β) and the 60-min insulinogenic index (IGI60). Linear-regression models adjusted for age and early-pregnancy body mass index examined the associations between each lipid marker and continuous HOMA-IR and the Matsuda index as the primary analyses and with HOMA-β and IGI60 as the secondary analyses. Binary logistic-regression and receiver operating characteristic analyses of cohort-defined low insulin sensitivity were exploratory. After adjustment for age and early-pregnancy body mass index, all seven lipid markers were significantly associated with continuous HOMA-IR and the Matsuda index (all nominal P < 0.05). No statistically significant associations were observed with the surrogate β-cell-function indices HOMA-β or IGI60. In the exploratory analyses, the lipid markers were associated with the cohort-defined low-Matsuda category. Triglycerides/high-density lipoprotein cholesterol had the highest observed area under the curve in the total population (0.723; 95% confidence interval 0.689-0.756). The exploratory cutoff selected by maximizing Youden's index was 0.65, with a sensitivity of 74.1% and a specificity of 62.5%. First-trimester lipid markers were associated with second-trimester IR and insulin-sensitivity indices, whereas no statistically significant associations were observed with the surrogate BCF indices used in this study. Triglycerides/high-density lipoprotein cholesterol showed moderate apparent discrimination for cohort-defined low insulin sensitivity and should be considered a hypothesis-generating candidate marker requiring external validation.

PMID 43040868
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多insulin